anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is designed to test the hypothesis that on an equivalent calorie basis, oat based breakfast cereals do not provide the same satiety benefit. The study will also demonstrate the satiety comparison of the cereals related to product density. Ninety-six healthy men and women 18 years of age or older will be enrolled into this study and divided into 2 groups of 48 each to investigate the satiety impact of two oat based breakfast cereals compared to the leading ready-to-eat (RTE) oat based breakfast cereal. Each subject will participate in two test sessions (1 test cereal vs the leading RTE cereal). Subjects will come to the Ingestive Behavior Laboratory between 8 and 10 am after having nothing to eat for 10 hours prior to the scheduled visit time and be given one of the three cereals. The second session will be scheduled at least 1 week after the first. Visual analogue scales of hunger, satiety and subjective energy will be completed at baseline, 30, 60, 120, 180, and 240 minutes. Subjects will return on another day separated by at least a week to repeat the breakfast. Area under the curves of appetite and satiety will be compared with a mixed model.
PROBLEM TO BE SOLVED: To obtain the subject composition showing good dyeing characteristics, fade-proofness or the like by including an acid dye or natural dye, aromatic alcohol and glycolic acid, and by using it in a specific pH range and buffer capacity range. SOLUTION: This composition contains (A) 0.01 to 2wt.% of an acid dye (e.g. nitro dye) or natural dye (e.g. carotenoid- or anthraquinone-based dye), (B) 0.5 to 20wt.% of an aromatic alcohol (e.g. benzyl alcohol) and (C) 0.1 to 20wt.% of glycolic acid and its salt (e.g. ammonium salt of glycolic acid) as the buffer agent, wherein a 10% aqueous solution of the hair dye composition is adjusted at pH 2.0 to 7.5 and buffer capacity (concentration of a base needed to increase pH level of the 10% aqueous solution of the hair dye composition from the initial level by 1 at 25 deg.C) at 0.01g-equivalents/1 or more but less than 0.5g-equivalents/1, to obtain the objective composition.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to ophthalmology, and concerns treating chronic bacterial conjunctivitis. That is ensured by bacteriophage instillations in a conjunctival cavity considering drug sensitivity of a bacterial flora. It is combined with nasolacrimal duct irrigation for the first 3-4 days with the bacteriophage preparation, also injected into nasal passages and used to irrigate a pharyngeal mucosa. The therapy is within 10 days, for at least 5 times a day. ^ EFFECT: method provides reduction of the symptoms of a bacterial conjunctivitis on the 3-4th day of treatment, decreased number of recurrences due to simultaneous sanitation of all reservoirs of bacterial infection. ^ 2 ex
Doripenem is an antibiotic medication not yet approved by the US FDA. This is a phase 3, multi-center, randomized, prospective, double-blind study of doripenem versus comparator in the treatment of complicated lower urinary tract infections (UTI) or pyelonephritis in adults. After the screening, patients are randomized to receive either doripenem or comparator. Patients are hospitalized, but subsequently, patients may be treated as outpatient or through home-based therapy at the investigators' discretion. Conventional laboratory data are collected from all patients at specified times throughout the study. The primary endpoint is microbiological response measured at test of cure visit. The patients receive either doripenum or comparator; duration of therapy is 10 days.
BACKGROUND: Finasteride is commonly prescribed for androgenic alopecia and benign prostatic hyperplasia. However, concerns regarding its safety have been growing as cases of cognitive dysfunction have been reported.
METHODS: A disproportionality analysis was conducted on data collected between 1967 and 2022 to explore the potential association. Cases of cognitive dysfunction associated with finasteride use were identified, and the reporting odds ratio (rOR) was calculated with 95% confidence intervals to determine the strength of the association between the two variables. Sensitivity analyses were conducted to account for confounding by indication.
RESULTS: Among the 54,766 cases of adverse events reported for finasteride use, 1,624 (2.97%) were associated with cognitive dysfunction. The study found a significant disproportionality for cognitive dysfunction related to finasteride use (rOR 5.43, 95% CI 5.17-5.71). Most cases were considered serious (65.83%), with no signs of recovery (58.37%). Sensitivity analyses showed that patients younger than 45 years (rOR 7.30, 95% CI 6.39-8.35) and those with alopecia (rOR 5.52, 95% CI 5.15-5.91) reported more cognitive dysfunctions than their counterparts.
CONCLUSION: This study showed an increased reporting of cognitive dysfunction associated with finasteride use, especially among younger alopecia patients. Finasteride should be prescribed with caution, especially to younger alopecia patients.
The invention relates to a traditional Chinese medicine composition for treating pulmonary emphysema of a sheep. The traditional Chinese medicine composition for treating the pulmonary emphysema of the sheep is prepared from radix platycodonis, radices ophiopogonis, rhizoma pinelliae, semen lepidii, jujubes, fritillary bulbs, rhizoma phragmitis and peach seeds. The traditional Chinese medicine composition can be pulvis. A preparation method of the traditional Chinese medicine composition comprises the steps that 1, all the traditional Chinese medicines are weighed according to the formula ratio; 2, water with the weight equal to two to three times of that of all the medicines is added to the medicines through an infiltration method to ensure that the medicines are soaked and the water does not exist; 3, depressurization drying is conducted at the temperature ranging from 40 DEG C to 70 DEG C till complete drying is achieved; 4, the dried medicinal materials are smashed through a pulverizer, and the smashed medicinal materials are screened through a sieve with 30-100 meshes; 5, mixing is conducted for 10-15 min to obtain traditional Chinese medicine powder; 6, bag packing is conducted, the weight of each bag ranges from 100 g to 200 g, and a finished product is obtained. The traditional Chinese medicine composition for treating the pulmonary emphysema of the sheep has the effects of diffusing the lung, eliminating phlegm, relieving a sore throat, expelling pus, moistening the lung for arresting a cough, clearing heat and dissipating the phlegm. By means of the traditional Chinese medicine composition for treating the pulmonary emphysema of the sheep, a definite curative effect is achieved, and the effective rate can reach 95.1 percent.
Closure of GI defects after endoscopic resection decreases the rate of post resection bleeding. Traditionally, standard TTS clips have been used to close GI wall defects with some success. However, complete apposition of the resection wall edges occurs only 68% of the time. Endoscopic suturing with the traditional Overstitch device can achieve complete closure in almost 100% of defects. However, this device is costly, requires the use of a double channel therapeutic endoscope, and at times can be difficult to maneuver. Recently, a novel FDA approved TTS tissue helix and suture device (X-tack) was developed to overcome the challenges of the traditional Overstitch device. Animal models have demonstrated the X-tack system is superior to TTS in effecting large mucosal defects and maintain similar durability. At BCM, we have been using the X-tack system routinely in closure of GI defects.
Novel Nd  - phthalyl - L - orinthine derivatives of the formula <FORM:1089771/C2/1> wherein R and R1 represent hydrogen, halogen, C1- 7 alkyl, nitro or C1- 7 alkoxy, Y represents hydrogen, an alkali metal or a group capable of protecting the acid radical or of activating the said radical in peptide synthesis and Z represents hydrogen or a group capable of protecting the amino radical in peptide synthesis, and acid addition salts of such compounds, are prepared by reacting ornithine with a copper salt, treating the resulting ornithine copper complex with a compound of the formula <FORM:1089771/C2/2> wherein the lower alkyl radical contains one to seven carbon atoms, and treating the resulting phthalyl-ornithine copper complex with water, H2S or an acid to destroy said complex. The above Nd  - phthalyl - L - ornithine derivatives may be reacted with a peptide or an amino acid or an ester thereof in a liquid phase in the presence of an excess of an organic base followed by acidification of the reaction mixture to yield a corresponding Nd  - (substituted or unsubstituted) - phthalyl - ornithine - containing peptide. This latter class of compounds may be reacted with at least one further amino acid, peptide or ester thereof to obtain corresponding higher Nd  - (substituted or unsubstituted) - phthalyl-ornithine containing peptides.  Dephthalylation, e.g. by treatment with hydrazine, may be carried out after any peptide formation step to yield the corresponding (Nd -unsubstituted ornithine)-containing peptides.  The latter compounds may be further guanylated, e.g. by treatment with 1 - guanyl - 3,5 - dimethylpyrazole, to yield corresponding arginine - containing peptides. Using the above procedures, dephthalylation to give S - benzyl - N - benzyloxycarbonyl - L - cysteinyl - L - tyrosyl - L - phenylalanyl - L - glutaminyl - L - asparaginyl - S - benzyl - L - cysteinyl - L - propyl - L -ornithyl - glycinamide may be followed by reduction with an alkali metal and liquid ammonia and subsequent oxidation to yield 8-L-ornithine vasopressin. Insertion of a guanylation step prior to the reduction step gives after oxidation 8-L-arginine vasopressin.  8 - L - ornithine vasotocin and 8-L-arginine vasotocin are obtained similarly from S - benzyl - N - benzylcxycarbonyl - L-cysteinyl - L - tyrosyl - L - isoleucyl - L - glutaminyl - L - asparagynyl - S - benzyl - L - cysteinyl - L - prolyl - L - ornithyl - glycinamide. Tertiary - butyl Na  - benzyloxycarbonyl - L - tryptophylglycinate is prepared by reacting benzyloxycarbonyl - L - tryptophane nitrophenyl ester with glycine tertiary-butyl ester. Tertiary - butyl - L - tryptophylglycinate is prepared by hydrogenation of the corresponding Na -benzyloxy compound.  This product may be isolated as the oxalate.
In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
The recommended usual dosage range of trandolapril for hypertension is 1 to 4 mg per day administered in a single dose or two divided doses. The recommended usual dosage range of Isoptin-SR for hypertension is 120 to 480 mg per day administered in a single dose or two divided doses. 

The hazards (see WARNINGS) of trandolapril are generally independent of dose; those of verapamil are a mixture of dose-dependent phenomena (primarily dizziness, AV block, constipation) and dose-independent phenomena, the former much more common than the latter. Therapy with any combination of trandolapril and verapamil will thus be associated with both sets of dose-independent hazards. The dose-dependent side effects of verapamil have not been shown to be decreased by the addition of trandolapril nor vice versa. 

Rarely, the dose-independent hazards of trandolapril are serious. To minimize dose-independent hazards, it is usually appropriate to begin therapy with TARKA only after a patient has either (a) failed to achieve the desired antihypertensive effect with one or the other monotherapy at its respective maximally recommended dose and shortest dosing interval, or (b) the dose of one or the other monotherapy cannot be increased further because of dose-limiting side effects.

Clinical trials with TARKA have explored only once-a-day doses. The antihypertensive effect and or adverse effects of adding 4 mg of trandolapril once-a-day to a dose of 240 mg Isoptin-SR administered twice-a-day has not been studied, nor have the effects of adding as little of 180 mg Isoptin-SR to 2 mg trandolapril administered twice-a-day been evaluated. Over the dose range of Isoptin-SR 120 to 240 mg once-a-day and trandolapril 0.5 to 8 mg once-a-day, the effects of the combination increase with increasing doses of either component.
BACKGROUND: Cardiovascular calcification is a pervasive issue throughout chronic kidney disease (CKD) progression. Autophagy, a fundamental cellular process, exerts significant influence on various cardiac pathologies, including arrhythmias, atherosclerosis, heart failure, and notably, valvular, and vascular calcifications. Beclin-1, a crucial eukaryotic protein, plays a major regulatory role in autophagy as part of the phosphatidylinositol-3-kinase (PI3K) complex. Recent evidence suggests a protective role for Beclin-1-mediated autophagy in CKD vascular calcification, raising its potential as a novel therapeutic target in this context.
WE AIMED TO: Investigate the association between serum Beclin 1 levels and the presence of cardiovascular valvular calcification in hemodialysis patients.
RESULTS: This study evaluated a cohort of 102 hemodialysis patients, evenly divided into two groups based on echocardiographic findings. All participants underwent serum Beclin 1 measurement and transthoracic echocardiography. Patients with acute kidney injury, active malignancy, or diabetes were excluded. Our study revealed significant differences between the two groups in terms of: Serum Beclin 1 levels, all parameters of lipid profile, prevalence of ischemic heart disease, serum albumin levels and Total calcium. Echocardiography in Group 1 showed that most cases (60.78%) exhibited mild aortic valve calcification. Additionally, significant relationships were observed between Beclin 1 and: ischemic heart disease (p=0.011) Aortic valve calcification on echocardiography (p < 0.001) Interestingly, lower Beclin 1 levels were associated with more severe valve calcification. A Beclin 1 cutoff value of ≤ 35.5 ng/ml demonstrated the highest sensitivity (98%) and specificity (92%).
CONCLUSION: Our findings suggest that the serum Beclin 1 level could be incorporated into a predictive model for cardiac valvular calcification in hemodialysis patients.
Computer-implemented methods and systems for creating pre-configured claim reports including estimated liability for a vehicle accident are provided. In an embodiment, claim information on a computer system required by a pre-configured claim report for an accident may be accessed from a database. In some embodiments, the claim information may be accessed if a user-specified condition is met. In other embodiments, the claim information may be accessed periodically following a user-specified time period. A pre-configured claim report may be created from the accessed claim information. In certain embodiments, the pre-configured claim report may be sent to a user-specified location.
During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
OBJECTIVE: To investigate the early predictive value of halving time (HT) of BCR-ABLIS for deep molecular response (DMR) in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitor (TKI).
METHODS: The continuous data of newly diagnosed CML patients with complete case data and first-line imatinib treatment admitted to the Affiliated Hospital of Inner Mongolia Medical University from January 2014 to June 2022 were retrospectively analyzed. Combined with the clinical characteristics of the patients and the efficacy analysis at each time point, a logistic regression model was used to explore the independent influencing factors of DMR, and combined HT of BCR-ABLIS with BCR-ABLIS level at 3 months to predict DMR of the patients.
RESULTS: Univariate and multivariate analyses showed that HT and 3-month BCR-ABLIS levels were independent influencing factors for MR4, MR4.5, and stable MR4.5 ( P < 0.05). ROC curve analysis determined that the best cut-off value of HT was 28 days. Compared with patients with HT>28 d, patients with HT≤28 d were more likely to obtain DMR at 2, 3, and 5 years, respectively (74.2% vs 27.3%, 71.2% vs 22.7%, and 63.6% vs 25.0%, all P < 0.001). The patients were divided into 4 groups according to BCR-ABLIS levels at 3 months and HT. Kaplan-Meier analysis showed that the patients in the BCR-ABLIS≤10% and HT≤28 d group had a higher probability of obtaining cumulative MR4 and MR4.5 than those in the BCR-ABLIS≤10% and HT>28 d group (P < <0.05); Patients in the BCR-ABLIS>10% and HT≤28 d group had a higher probability of obtaining cumulative MR4 and MR4.5 than those in the BCR-ABLIS>10% and HT>28 d group ( P < 0.05).
CONCLUSION: In addition to BCR-ABLIS level, HT of BCR-ABLIS can be used as another important predictor of treatment efficacy in CML patients. The combination of BCR-ABLIS level and HT has a more accurate predictive value for long-term molecular response of CML patients after TKI treatment.
Motor imagery is a cognitive process that the person continues mentally without actually performing a particular motor movement. The concept of motor imaging has become more and more important in recent years and has allowed us to obtain different ideas about the emergence of motor movements. When the literature is analyzed, it was reported that the brain areas activated during the motor movement of individuals overlap with the active areas in the imaging process.As an individual's ability to imagine movement increases, the centers participating in the motor system become so activated. In the literature, it has been stated that this motor imaging ability may decrease in people who have had a stroke. For this reason, the motor imagination ability of the person should be evaluated before a suitable rehabilitation program is decided.When we look at the literature, it was seen that the Movement Imagery Questionnaire - Revised Second was used to evaluate the patients with subacute and chronic stroke, and there was no validity and reliability study in patients with acute stroke. Considering this situation, it was planned to translate the Movement Imagery Questionnaire -RS questionnaire into our language within the scope of our study and then to investigate the reliability and validity of patients with acute stroke.
Several investigators have reported that sarcopenia is common in patients with liver cirrhosis. However, few studies have probed the association between sarcopenia and liver cirrhosis complicated with oesophageal and gastric variceal bleeding (LC-EGVB). We aimed to investigate the impact of sarcopenia on rebleeding after endoscopic therapy in patients with LC-EGVB. Computed tomography (CT) radiographs from the third lumbar vertebra were selected to analyse body composition, including skeletal muscle tissue, visceral and subcutaneous adipose tissue using SliceOmatic software. Sarcopenia was defined using validated cutoff values for patients with liver cirrhosis: 44.77 cm2/m2 for men and 32.50 cm2/m2 for women. A total of 187 patients with LC-EGVB and 309 controls were included in this study. The rate of sarcopenia in controls (17.4 %) was significantly lower than that in patients with LC-EGVB (41.2 %). Patients with LC-EGVB exhibiting sarcopenia showed a high prevalence of portal vein thrombosis and rebleeding rate at 1 year. The rate of sarcopenia in the rebleeding group was significantly higher than that in the non-rebleeding group. Univariate and multivariate analyses showed that sarcopenia was an independent risk factor for rebleeding within 1 year in patients with LC-EGVB. Patients with LC-EGVB displayed a high prevalence of sarcopenia. Sarcopenia was observed to be an independent risk factor for rebleeding within 1 year.
PURPOSE: A monoclonal antibody to proteinase-3 as an agent for treating or diagnosing stroke is provided to develop novel drugs for effectively treating stroke. CONSTITUTION: A composition for preventing or treating stroke contains an antibody to proteinase-3 as an active ingredient. The proteinase-3 has an amino acid sequence of sequence number 1. The composition suppresses neuronal cell damage and inflammation. A composition for diagnosing stroke contains the antibody as an active ingredient. A method for preparing the antibody comprises: a step of injecting the proteinase-3 protein to an animal to immunize; and a step of isolating antibody from the serum of the animal.
For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
The invention discloses a kind of method of extracting polysaccharide from Chinese caterpillar fungus culture medium, is that Cordyceps militaris is pulverized, add water and be mixed in 30～80 DEG C of lixiviates in enzyme liquid or alkali lye, and centrifugation, insoluble matter repeats to extract, and merges supernatant. In 50～75 DEG C of amylase enzymolysis, after centrifugation, supernatant concentration, to sugary 1.5～3.0%, adds ethanol, alcohol precipitation at 0～4 DEG C, the centrifugal rear dry product that to obtain. Through de-albumen, after dialysis, obtain the thick polysaccharide of Chinese caterpillar fungus. Can adopt single enzyme, two enzyme, complex enzyme and ultrasonic wave enzyme process, enzyme can be selected protease, trypsase etc. The present invention has optimized the process route that extracts Cordyceps sinensis polysaccharide, has improved yield and the extraction efficiency of Cordyceps sinensis polysaccharide, effectively carries out Cordyceps sinensis polysaccharide extraction, separation and purification. The present invention both provided a kind of solution route to the utilization of agricultural wastes, also for the further exploitation of Cordyceps sinensis polysaccharide provides technical foundation.
The control group receives 10 weeks of "treatment as usual (TAU)" (that is the standard psychoeducation, support and treatment given to all youth after neuropsychiatric assessment at our clinic), followed by 10 weeks of PR-ESSENCE. Outcome measures were collected pre- and post-treatment, and after 6 months and one year.
The invention relates to the technical field of biological medicine, in particular to application of cyclosporine in preparation of a medicine for treating right ventricular diseases, wherein the right ventricular myocardium of a mouse is pathologically remodeled 7 days after volume load through volume load operation on the mouse in an infant stage: myocardial wall thickening, vascular proliferation, and disordered cell arrangement represent success in constructing animal models. Cyclosporine (12.5mg/kg. d,0.5ug/ul) was then injected subcutaneously for 1-7 days post-surgery, indicating that: the right ventricular myocardial wall of the mouse becomes thin, blood vessels are reduced, and the cell arrangement tends to be normal. Right ventricular free wall transcriptome sequencing was performed 7 days after surgery, and differential gene thermographs showed that the right ventricular myocardial gene expression of mice loaded with cyclosporine was close to that of mice in the sham operated group. The results indicate that cyclosporin has a therapeutic effect on the pathological remodeling of the right ventricle in infants and young children caused by volume load. The invention discovers the new medical application of the cyclosporine for the first time, and is expected to improve the long-term life quality of children patients with congenital heart disease.